Irlab Therapeutics Ab Class A · OMXSTO:IRLAB_A
Irlab Therapeutics Ab Class A — Q3 2021 Earnings Presentation
23 slides from Irlab Therapeutics Ab Class A's earnings presentation, November 2021
Slide 1: Transforming life for patients with Parkinson's disease
Transforming life for patients with Parkinson’s disease IRLAB Interim report July- September 2021
Slide 2: IRLAB: Better positioned than ever before
IRLAB: Better positioned than ever before • In partnership with a global pharma company • Strong cash position • Two programs with exciting prospects in clinical development • Several development candidates towards clinical trials • Interest in IRLAB assets is high and growing We have every reason t
Slide 3: Our purpose and drive
Our purpose and drive Introduction What? Why? How? IRLAB strives to meet the IRLAB wants to transform the With IRLAB’s cutting-edge need for novel drugs to treat lives of people with expertise in modern diseases of the central Parkinson’s disease. discovery and development, nervous system, with a fo
Slide 4: Financial summary
Financial summary Opex per item Operating result (MSEK) Cash balance (MSEK) 40 140 500 35 120 450 30 100 400 25 350 80 20 300 60 15 250 40 10 200 20 150 5 0 100 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 -20 50 2019 2019 2019 2019 2020 2020 2020 2020 2021 2021 2021 -40 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q1
Slide 5: Path to deliver strong growth
Path to deliver strong growth Outlook Foundation for Building for Delivering first-in- transformative the future class treatments treatments in transforming Parkinson’s standard of care in Parkinson’s 2020 - 2022 2023 - 2024 2025 - 2026 Mesdopetam Mesdopetam Mesdopetam Successful completion of Phase
Slide 6: One of the largest licensing agreements in Swedish biotech
One of the largest licensing agreements Mesdopetam in Swedish biotech IRLAB licenses worldwide rights for Mesdopetam to Ipsen Type Global, mid-sized IRLAB Ipsen biopharmaceutical company Employees approx. 5,700 worldwide • Receives • Obtains the exclusive worldwide • $28 million upfront license to d
Slide 7: Impact of mesdopetam license
Impact of mesdopetam license • Internal R&D resources freed up • Up-front from mesdopetam license + SEK 240m • Cash position SEK 431m • Net revenues Q3 SEK 196m • License and services • Operating profit Q3 SEK 120m • Potential milestones USD 335m • Reduced cost coming 18mo + SEK 100m 7
Slide 8: Significant revenue and reduced costs facilitate growth
Significant revenue and reduced costs facilitate growth IRLAB to the next level business-oriented company Employees 2018-2021 30 • Increased R&D • Increased clinical operations 25 • Increased IR and business development 20 15 Organizational focus on • Pirepemat – Prevention of falls 10 • P001 – To p
Slide 9: Pipeline generated by proprietary technology platform: ISP
Pipeline generated by proprietary Introduction technology platform: ISP ISP – a new level of rational, systems-oriented drug discovery • Advanced systems biology interlinked with drug design and machine learning (ML, AI) techniques • Enabled through extensive, high quality ISP database IRLAB’s ISP g
Slide 10: Portfolio transforming treatment of patients with Parkinson's
Portfolio transforming treatment of Introduction patients with Parkinson’s Mesdopetam * Partnering strategy • To increase ”good ON”-time through • 2021: Partnered with reduction of dyskinesias (PD-LIDs) IPSEN in a global • To treat psychosis in Parkinson’s (PD-P) licensing deal Pirepemat • Improve b
Slide 11: IRLAB: Better positioned than ever before
IRLAB: Better positioned than ever before • A partne rship with a global pharma company, • A strong cash position, • Ne w proje cts with ve ry e xciting prospe cts in clinical de ve lopme nt • Se ve ral de ve lopme nt candidate s on the ir way towards clinical trials • Inte re st in IRLAB asse ts is
Slide 12: Living with Parkinson's: IRLAB transforms the treatment algorithm
Living with Parkinson’s: IRLAB transforms Introduction the treatment algorithm Initial symptoms before diagnosis Parkinson’s diagnosis Early-stage Advanced/late-stage IRLAB’s solution Psychiatric Cognitive impairment Psychosis Mesdopetam Hallucinations Dementia Apathy Depression Non-motor Pirepemat
Slide 13: Preclinical: P001 and P003 projects
Preclinical: P001 and P003 projects P001: Innovative strategies to promote brain health. Wide utility in CNS disorders related to cortical dysfunction (PD, dementias, ADHD, schizophrenia, depression) P003: Innovative strategies to improve the treatment of core symptoms of Parkinson's disease 13
Slide 14: Preclinical projects: Therapeutic response
Preclinical projects P001: Innovative strategies to amplify cortical synaptic connectivity and promote brain health • Restore cortical signaling in neurological & neuropsychiatric indications with deficient cognitive functioning • Besides PD dementia, preclinical data supports potential in multiple
Slide 15: Pirepemat (IRL752)
Pirepemat (IRL752) Improve balance and reduce falls in Parkinson’s (PD-Falls)
Slide 16: Pirepemat is designed to improve balance and reduce falls in Parkinson's
Pirepemat is designed to improve Pirepemat balance and reduce falls in Parkinson’s PD-Falls patient population EU5 – A large unmet need (DE, ES, FR, IT, UK) • 45% of all people with Parkinson’s fall US recurrently 565,000 JP • Impaired balance and a fear of falling 470,000 275,000 395,000 CN signifi
Slide 17: Clinical Phase IIb: Impaired balance/Falls
Clinical Phase IIb: Impaired balance/Falls pirepemat Phase IIb study “A Phase IIb to evaluate the effects of pirepemat on falls frequency as compared to placebo.” Secondary & other objectives • To evaluate the effects of pirepemat on cognitive functions assessed with Montreal Cognitive Assessment (M
Slide 18: Clinical Phase IIb: Study overview
Clinical Phase IIb: Study overview pirepemat Phase IIb study Clinical assessments Falls diaries Screening Baseline Visit 3 Visit 4 Visit 5 Visit 6 Visit 7 Visit 8 Follow-up Placebo IRL752 300 mg IRL752 600 mg Screening 4-6 weeks Treatment period 12 weeks FU ~2 weeks after End of Treatment First week
Slide 19: Mesdopetam (IRL790)
Mesdopetam (IRL790) Improve motor function through prevention and reduction of dyskinesias (LIDs) Treatment and prevention of psychosis in Parkinson’s (PD-P) • Currently in development with partner Ipsen who holds an exclusive global license to develop and commercialize mesdopetam • (https://www.irl
Slide 20: Parkinson's disease levodopa-induced dyskinesia – an unmet need
Parkinson’s disease levodopa-induced Mesdopetam dyskinesia – an unmet need PD-LIDs patients globally • >30% of people with Parkinson’s disease develop LIDs EU5 (DE, ES, FR, IT, • Dyskinesias overshadow the necessary UK) treatment benefits of levodopa treatment and US 230 000 JP reduces “good ON”-tim
Slide 21: Wide clinical potential in unmet medical needs in neurology
Wide clinical potential in unmet medical Mesdopetam needs in neurology PD-LIDs PD-P TD Levodopa-induced dyskinesias Parkinson’s disease psychosis Tardive dyskinesia • Affects about 25% of patients • Affects about 35% of patients • Affects about 25% of psychiatric with Parkinson’s with Parkinson’s, o
Slide 22: Contact
Contact: Åsa Hillsten, IR, asa.hillsten@irlab.se, Viktor Siewertz, CFO, viktor.siewertz@irlab.se, Nicholas Waters, CEO, nicholas.waters@irlab.se, IRLAB is a Swedish research and drug development company that focuses on developing novel treatments in Parkinson’s disease. The company’s most advanced c
Slide 23: Disclaimer
Disclaimer This document, “IRLAB Therapeutics” (the “Presentation”), has been prepared by IRLAB Therapeutics AB (publ) (“IRLAB”) and is provided for informational purposes only. All information in this Presentation has been compiled in good faith by IRLAB. Neither IRLAB nor any of its directors, emp